Department of Urology
Ph.D., Maharishi Dayanand University, (Rohtak), India, 1998
Postdoctoral, France, UNMC, University of Iowa, 1998-2006
Dr. Karan's laboratory is involved in immunotherapy studies using prostate cancer model addressing the role of immune system in antitumor therapy, activation of antitumor responses and characterization of antitumor effector mechanisms. His laboratory has developed a viral-based tumor vaccine inducing tumor-specific immunity for a simultaneous targeting of multiple epitopes specific to prostate cancer cells. Currently his lab is investigating the immune and antitumor responses induced by uniquely designed multivalent vaccine, and the role immune responses play in the destruction of antigen-bearing prostate tumors. A separate component of immunotherapy studies is to further improve the effector function of immune T cells using toll-like receptor-9 agonist (CpG-ODNs) in combination with viral vaccine.
We are studying the gene expression analysis to identify the immunological markers that could help in predicting the benefit of immunotherapy studies. Gene expression studies also involve identification of signature molecules associated with the development and progression of hormone-refractory prostate cancer using both in vitro and in vivo mouse models.
Studies to better understand the development and progression of prostate cancer in response to prostate inflammation, and to generate novel approaches to improve the therapeutic modalities are in progress. In this context, his laboratory is investigating the functional regulation of a previously identified protein associated with macrophage activation and inflammation in the prostate.
Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF. 2006. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13(1): 151-167.
Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M and Krieg A. 2006. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG-ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 24: 6155-6162.
Chen SJ, Karan D, Johansson SL, Singh AP, Batra SK, and Lin MF. 2007. Prostate-drived factor promotes the proliferation of androgen receptor (AR)-positive human prostate cancer cells. The Prostate 67(5): 557-571.
Karan D, Krieg A and Lubaroff D. 2007. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Intl J Cancer 121: 1520-1528.
Karan D, Thrasher JB and Lubaroff DM. 2008. Prostate cancer: genes, environment, immunity and the use of immunotherapy. Prostate Cancer and Prostatic Diseases 11(3): 230-236.
Karan D, Holzbeierlein J and Thrasher JB. 2009. Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Research 69(1): 2-5.
Lubaroff DM and Karan D. 2009. CpG Oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev 61: 268-274.
Karan D, Dubey S, Holzbeierlein JM, VanVeldhuizen P, Tawfik O and Thrasher JB. 2011. Dual antigen target based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy 3(6): 735-746.
Dubey S, VanVeldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB and Karan D. 2012. Inflammation associated regulation of macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. Oncology Letters 3: 1166-1170.
Karan D, Holzbeierlein JM, VanVeldhuizen P and Thrasher JB. 2012. Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nature Reviews Urology 9(7): 376-385.
Karan D and Van Veldhuizen P. 2012. Combination immunotherapy with prostate GVAX and ipilimumab: saftey and toxicity. Immunotherapy 4(6): 577-580.
Dev Karan, Ph.D.